ALXO ALX Oncology Holdings

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer



  • Conference Call and Webcast Today at 4:30 PM EDT



SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.

To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 9637001. To access the live and archived webcast of the conference call, please visit the News & Events section (see “") of the Company’s website at , where a slide presentation will be referenced during the event.



Company Contact: Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology,  , (650) 466-7125

Investor Contact: Malini Chatterjee, Ph.D, Blueprint Life Science Group, (917) 330-4269

Media Contact: Audra Friis, Sam Brown, Inc.,  , (917) 519-9577 
EN
31/07/2024

Underlying

ALXOALX Oncology Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALX Oncology Holdings

 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcar...

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today that management will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 17 – 19, 2024. Format: Fireside chat with analyst, Li Watsek and 1x1 meetingsDate: Tuesday, September 17, 2024 Time: 1:55 PM ...

September 9, 2024 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarcli...

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced the first patients have been dosed in an arm o...

September 4, 2024 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Reports Second Quarter 2024 Financial Results and Provide...

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. “Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications,” said Jason ...

August 8, 2024 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors - Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave board to focus on ALX leadership responsibilities as Company’s clinical program advances - SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today the appointment o...

August 6, 2024 1 EN
 PRESS RELEASE
Free
ALXO ALX Oncology Ho...

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstr...

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm and demonstrated a median duration of response of 15.7 months compared to 7.6 months in the full trial populationIn the pre-specified population of patients with fresh HER2...

July 31, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch